TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10223915

Group type: EXPERIMENTAL
Intervention: Gatifloxacin alone (treatment A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gatifloxacin alone (treatment D)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aluminum magnesium hydroxide 2 h before gatifloxacin (treatment B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aluminum magnesium hydroxide concomitant with gatifloxacin (treatment C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aluminum magnesium hydroxide 2 h after gatifloxacin (treatment E)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aluminum magnesium hydroxide 4 h after gatifloxacin (treatment F)
Number of subjects: 24
Study: 7879932

Group type: EXPERIMENTAL
Intervention: Propofol 1.10 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketamine 0.39 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of Propofol 0.63 mg/kg and Ketamine 0.21 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Propofol 1.85 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketamine 0.66 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of Propofol 1.05 mg/kg and Ketamine 0.35 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Propofol 1.61 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketamine greater than 0.85 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of Propofol 1.50 mg/kg and Ketamine 0.50 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of Propofol and Ketamine
Number of subjects: 180

Group type: COMPARATOR
Intervention: All groups (Propofol, Ketamine, Combination)
Number of subjects: 180
Study: 2095311

Group type: EXPERIMENTAL
Intervention: Mouthwash containing purified endo-alpha-1, 3 glucanase (mutanase)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 22
Study: 701072

Group type: EXPERIMENTAL
Intervention: Lioresal (antispasticity drug)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30601452

Group type: EXPERIMENTAL
Intervention: TX‐001HR (17β‐estradiol and progesterone combined in a single, oral, softgel capsule)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: TX‐001HR
Number of subjects: 726
Study: 27312565

Group type: EXPERIMENTAL
Intervention: Energy Drink A (less sugar, no taurine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Energy Drink B (caffeine, undetermined energy blend)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Energy Drink C (caffeine, undetermined energy blend)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Carbonated water (control)
Number of subjects: 80
Study: 25811847

Group type: EXPERIMENTAL
Intervention: FMS + CHX
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: QS + CHX
Number of subjects: 100

Group type: COMPARATOR
Intervention: FMS
Number of subjects: 100
Study: 23580602

Group type: EXPERIMENTAL
Intervention: Electrokinetically modified water (EMW)
Number of subjects: 40
Study: 21934569

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner therapy (PDPT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: inSPOT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: inSPOT/PDPT
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard partner management
Number of subjects: 75
Study: 19728711

Group type: EXPERIMENTAL
Intervention: Porridge with 4 g of beta-glucan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granola with 4 g of beta-glucan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bread with 4 g of beta-glucan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasta with 4 g of beta-glucan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control products with low beta-glucan content
Number of subjects: 0
Study: 17911186

Group type: EXPERIMENTAL
Intervention: Argatroban therapy (N = 390; mean dose of 1.9 microg/kg/min for a mean 6 days)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Historical control therapy (N = 98)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Argatroban therapy
Number of subjects: 488
Study: 15819461

Group type: EXPERIMENTAL
Intervention: Quinine capsule
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quinine tablet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous infusion of quinine
Number of subjects: 12
Study: 11688589

Group type: EXPERIMENTAL
Intervention: FIS (Flexion in Standing)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EIS (Extension in Standing)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: FIL (Flexion in Lying)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EIL (Extension in Lying)
Number of subjects: 100

Group type: COMPARATOR
Intervention: All exercise groups (FIS, EIS, FIL, EIL)
Number of subjects: 100
Study: 9190868

Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg/2 min i.v.
Number of subjects: 38
Study: 1539815

Group type: EXPERIMENTAL
Intervention: Epidural morphine (0.2 mg/h) + epidural bupivacaine (10 mg/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural morphine (0.2 mg/h) alone
Number of subjects: 24
Study: 4002781

Group type: EXPERIMENTAL
Intervention: Muzolimine (M) 240 mg oral dose during dialysis (A)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Muzolimine (M) 240 mg oral dose after dialysis (B)
Number of subjects: 6
Study: 30844983

Group type: EXPERIMENTAL
Intervention: Bilateral resistance training (BIL, n = 13)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (UNI, n = 10)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison group (COM, n = 10)
Number of subjects: 33
Study: 30656180

Group type: EXPERIMENTAL
Intervention: Omaveloxolone 160 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Omaveloxolone 160 mg/day in patients without pes cavus
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 28763412

Group type: EXPERIMENTAL
Intervention: Tension-Band Wire (TBW) fixation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Plate fixation
Number of subjects: 67
Study: 26562376

Group type: EXPERIMENTAL
Intervention: Multi-layer soft silicone foam dressing applied to each heel
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group from the Border Trial
Number of subjects: 150
Study: 22402059

Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (ALA) 600 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (ALA) with and without vitamin E
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 21109389

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) at 3mg/kg per day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Azathioprine (Aza) at 1.5 to 2mg/kg
Number of subjects: 23
Study: 20002340

Group type: EXPERIMENTAL
Intervention: Massage therapy (20 minutes hands-on massage)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard preprocedural care (Control)
Number of subjects: 130
Study: 17383643

Group type: EXPERIMENTAL
Intervention: Adept (4% icodextrin solution)
Number of subjects: 402

Group type: COMPARATOR
Intervention: LRS (lactated Ringer's solution)
Number of subjects: 402
Study: 15065980

Group type: EXPERIMENTAL
Intervention: Positive character evidence (CE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: No character evidence (CE)
Number of subjects: 0
Study: 11384630

Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/d plus MPA 1.5 mg/d
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: CEE 0.45 mg/d plus MPA 1.5 mg/d
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: CEE 0.45 mg/d plus MPA 2.5 mg/d
Number of subjects: 2673

Group type: COMPARATOR
Intervention: CEE 0.625 mg/d plus MPA 2.5 mg/d
Number of subjects: 2673
Study: 9363407

Group type: EXPERIMENTAL
Intervention: INFORMED group (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: NON-INFORMED group (n = 11)
Number of subjects: 22
Study: 7691119

Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (230 micrograms/m2)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF
Number of subjects: 130
Study: 3768085

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 2645874

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 31403136

Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom (BV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28450138

Group type: EXPERIMENTAL
Intervention: Active tDCS (2mA, anode over F3 and cathode over F4, 20 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS (20 minutes)
Number of subjects: 20
Study: 25264109

Group type: EXPERIMENTAL
Intervention: Dorsiflexion assist orthosis (DAO) worn on the weaker leg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Walking without DAO
Number of subjects: 34
Study: 23842013

Group type: COMPARATOR
Intervention: Adjunctive agents in placebo-controlled clinical trials
Number of subjects: 59
Study: 21453896

Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway (CPLA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 60
Study: 17874036

Group type: EXPERIMENTAL
Intervention: Collagen-based closure device (group A) (n=214)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Suture-mediated device (group B) (n=152)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Angioseal device in PVD patients
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Perclose device in PVD patients
Number of subjects: 366
Study: 17073206

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Hybrid Bond
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Admira Bond
Number of subjects: 195
Study: 12483404

Group type: EXPERIMENTAL
Intervention: Commercially available amino acid solution (AA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lysine 25 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lysine 50 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lysine 75 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of 25 g of lysine plus 25 g of arginine (LysArg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fluid infusion alone (500, 1,000 or 2,000 ml of saline/glucose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No amino acid infusion (controls)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LysArg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lysine 75 g (Lys75)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Electrocardiographic analysis
Number of subjects: 6
Study: 10789936

Group type: EXPERIMENTAL
Intervention: CPAP via infant flow driver (IFD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CPAP via single nasal prong
Number of subjects: 36

Group type: COMPARATOR
Intervention: No CPAP
Number of subjects: 36
Study: 9561594

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (loading dose of 160 mg, followed by 80 mg daily for another 6 doses)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Quinine (intravenous infusion of loading dose of 20 mg/kg, followed by 10 mg/kg q 8 hourly for 7 days)
Number of subjects: 102
Study: 1555463

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: spirapril
Number of subjects: 21
Study: 3886401

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg three times daily for one week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg daily for one week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29490621

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2640 I.E. vitamin D3 q.d. for 28 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 27488750

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI)
Number of subjects: 49
Study: 25000149

Group type: EXPERIMENTAL
Intervention: Candle burning (CB)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Frying sausages (FS)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Toasting bread (TB)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 55
Study: 22787177

Group type: EXPERIMENTAL
Intervention: LY2605541
Number of subjects: 287

Group type: COMPARATOR
Intervention: Insulin Glargine (GL)
Number of subjects: 287
Study: 20409752

Group type: EXPERIMENTAL
Intervention: ETV6-RUNX1
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: High hyperdiploidy
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Intrachromosomal amplification of chromosome 21 (iAMP21)
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: t(9;22)
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: MLL translocations
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Abnormal 17p
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Loss of 13q
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Cytogenetic risk groups (good, intermediate, poor)
Number of subjects: 1725
Study: 19258967

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fascia iliaca block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Loss of resistance technique
Number of subjects: 80
Study: 15729085

Group type: EXPERIMENTAL
Intervention: N-PEP-12
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11597535

Group type: EXPERIMENTAL
Intervention: Diagnostic urethrocystoscopy
Number of subjects: 100
Study: 9532991

Group type: EXPERIMENTAL
Intervention: Transcervical amnioinfusion of 800 mL saline at 15 mL per minute, followed by a maintenance infusion at 3 mL per minute
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group received routine care
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Transcervical amnioinfusion of 800 mL saline
Number of subjects: 326
Study: 8127419

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitrazepam (5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2676650

Group type: EXPERIMENTAL
Intervention: Enterococcus SF68 (one capsule twice daily for prevention; three times daily for treatment)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Enterococcus SF68 (three times daily for treatment)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 1092130

Group type: EXPERIMENTAL
Intervention: 100 mg iron daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 11
Study: 31340116

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 305

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 305
Study: 29067756

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)–based single-pill dual-combination therapy (OM+amlodipine/azelnidipine or hydrochlorothiazide)
Number of subjects: 5888

Group type: COMPARATOR
Intervention: Olmesartan monotherapy
Number of subjects: 5888
Study: 27318919

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion at 0.5 μg/kg before induction and 0.2 μg/(kg×h) intraoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 25073269

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 100
Study: 22822562

Group type: EXPERIMENTAL
Intervention: Standard care with feedback benchmarked against other centers (benchmarking group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 19583073

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen 40 mg/kg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 104
Study: 17524249

Group type: EXPERIMENTAL
Intervention: HIV-positive PTB+ patients
Number of subjects: 655

Group type: COMPARATOR
Intervention: HIV-negative PTB+ patients
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: PTB+ patients
Number of subjects: 655
Study: 15158293

Group type: COMPARATOR
Intervention: Group 1 (25 and 20 kcal/kg for women <60 and >=60 years; 30 and 25 kcal/kg for men <60 and >=60 years)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Group 2 (5 kcal/kg higher than group 1)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 494
Study: 12228083

Group type: EXPERIMENTAL
Intervention: Internet-based curriculum on herbs and dietary supplements (10 weeks, 20 case-based modules)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Waiting-list group (control)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Both groups after completing the curriculum
Number of subjects: 537
Study: 9694050

Group type: EXPERIMENTAL
Intervention: Purified nucleohistone-binding antibodies from anti-DNA-depleted plasma IgG
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Purified antibodies from nephritis patient
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Adsorption of purified antibodies with histone
Number of subjects: 2
Study: 8137684

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 9
Study: 2551083

Group type: EXPERIMENTAL
Intervention: Intervention group with home care coordination by a nurse
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group with usual procedures
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 273
Study: 1132916

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Silence
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (Practice only)
Number of subjects: 39
Study: 31638969

Group type: EXPERIMENTAL
Intervention: Experiential education group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 28731778

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment algorithm
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: At least one psychiatric medication
Number of subjects: 40
Study: 25278336

Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo therapy (detuned ultrasound and shortwave therapy)
Number of subjects: 148
Study: 24022337

Group type: EXPERIMENTAL
Intervention: MCI subjects
Number of subjects: 153

Group type: COMPARATOR
Intervention: Previous personality traits
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 153
Study: 22352972

Group type: EXPERIMENTAL
Intervention: Eating disorders not otherwise specified (EDNOS) in males and females
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Unhealthy weight control methods
Number of subjects: 641
Study: 19390751

Group type: EXPERIMENTAL
Intervention: 10 mg riboflavin daily for 28 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17356099

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS) in patients with upper-lobe emphysema and low exercise capacity
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1218
Study: 15120716

Group type: EXPERIMENTAL
Intervention: Combination of stearidonic acid (1g/day) and gamma-linolenic acid (0.9g/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) consumption
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (2g/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of EPA with gamma-linolenic acid (GLA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Stearidonic acid (up to 1g/day)
Number of subjects: 8
Study: 11789361

Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluid diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 100
Study: 9048688

Group type: EXPERIMENTAL
Intervention: Regression model containing the Symptom Checklist Depression and Somatization scores, the one-month modified Roland-Morris score and the number of pain days in the past six months.
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Recursive partitioning model
Number of subjects: 1213
Study: 1645634

Group type: EXPERIMENTAL
Intervention: Low-frequency transcutaneous electrical nerve stimulation (TNS) at 2 Hz
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7235853

Group type: EXPERIMENTAL
Intervention: Weekly supportive group meetings
Number of subjects: 86
Study: 31953144

Group type: EXPERIMENTAL
Intervention: Decoy present (higher priced vegetarian options)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decoy absent (no higher priced vegetarian options)
Number of subjects: 0
Study: 31292045

Group type: EXPERIMENTAL
Intervention: Super Skills for Life (SSL) program
Number of subjects: 123

Group type: COMPARATOR
Intervention: Waiting list control (WLC) group
Number of subjects: 123
Study: 28643134

Group type: EXPERIMENTAL
Intervention: Volitional help sheet with implementation intentions
Number of subjects: 216

Group type: COMPARATOR
Intervention: Volitional help sheet without implementation intentions (control)
Number of subjects: 216
Study: 25194452

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus standard care
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 59
Study: 24473244

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory-cued (RAC) training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Speed-dependent treadmill training (SDTT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20